Glenmark to launch Lobeglitazone

Mumbai, Oct 6: Pharma major Glenmark Pharma became the first to launch Thiazolidinedione Lobeglitazone (Lobeglitazone) in India for the treatment of type 2 diabetes in adults.
Marketed under the brand name LOBG, it contains Lobeglitazone (0.5 mg) and to be taken once daily under prescription to improve glycemic control in adult diabetic patients.
Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled Type 2 diabetes among insulin resistant diabetic patients.
Glenmark’s LOBG is priced at approximately Rs 10 per tablet per day.
Glenmark earlier received approval from the Drug Controller General of India to manufacture and marketing Lobeglitazone based on a randomized, double blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older.
The results of this trial have shown a faster and improved glycemic control with Lobeglitazone.